The glutaminase inhibitor telaglenastat is being tested in the phase II ENTRATA study enrolling individuals who have received at least two lines of therapy for locally advanced or metastatic clear-cell renal cell carcinoma. Participants are randomly assigned to receive either telaglenastat or placebo alongside standard doses of everolimus.
Progression-free survival results will be presented at the ESMO 2019 Congress:
ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (tela; CB-839) + everolimus (E) vs. placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Saturday, 28 September: 08:30–08:45 (Abstract LBA54)
Presenter: Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA
Invited discussant: Ignacio Duran Martinez, Hospital Universitario Marqués de Valdecilla, Santander, Spain